Related Experiment Videos
[Dynamic thyroid hormone levels during the thyrostatic treatment of Basedow's disease]
Vutreshni Bolesti
|January 1, 1988
Summary
Thyrostatic treatment for Basedow's disease can lead to early remission. Monitoring thyroid hormones and thyrotropic hormone is crucial due to individual differences in thyroid suppressibility, requiring dose adjustments.
Area of Science:
- Endocrinology
- Pharmacology
Context:
- Basedow's disease (Graves' disease) management requires careful monitoring of thyroid function during thyrostatic therapy.
- Thyrostatic agents are commonly used to control hyperthyroidism in Graves' disease.
Purpose:
- To dynamically assess thyroid hormones and thyrotropic hormone (TSH) levels during thyrostatic treatment in new Basedow's disease patients.
- To identify patterns and individual variations in hormonal response to thyrostatic therapy.
Summary:
- Therapeutic remission was observed early, averaging 2.4 months.
- Thyrotropic hormone levels increased significantly post-remission, averaging 19.5 mIU/L by month four.
- Nine patients experienced initial hypothyroidism despite consistent treatment, indicating individual differences in thyroid suppressibility.
Impact:
- Highlights the need for dynamic monitoring of hormonal action during thyrostatic treatment.
- Emphasizes timely dose correction to prevent consequences of improper thyroid medication dosage.
- Suggests personalized treatment adjustments based on individual thyroid suppressibility.